Axis-Shield concludes new homocysteine contract
Dundee, Scotland. Axis-Shield plc announces that it has concluded a licensing agreement with Azwell Inc, of Osaka, Japan, to allow marketing of Azwell's homocysteine assay in the USA and Canada. Azwell's exclusively-licensed partner in the USA is Polymedco of Cortlandt Manor, New York. Polymedco will market Azwell's assay solely on its proprietary Poly-Chem analyser. Under the agreement, Axis-Shield will receive a royalty on each test sold by Polymedco.
Svein Lien, Axis-Shield Chief Executive Officer, commented: "We were pleased to be able to license Azwell to provide Polymedco with a homocysteine assay for its Poly-Chem clinical chemistry platform in the expanding US and Canadian markets."
Axis-Shield is an international in vitro diagnostics company, headquartered in Dundee with R&D and manufacturing bases in Dundee and Oslo. The Group specialises in the development, manufacture and marketing of innovative proprietary diagnostics kits in areas of clinical need, including cardiovascular and neurological diseases, rheumatoid arthritis, alcohol abuse and diabetes. It has a special focus on effective testing at the point of care, for improved patient management
Other news from the department business & finance
